Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
AuthorsPinedo, H M
Bramwell, Vivien H C
Mouridsen, H T
Vendrik, C P
Van Oosterom, A T
Van Unnik, J A
AffiliationDepartment of Medical Oncology, Free University Hospital and Netherlands Cancer Institute, Manchester, United Kingdom
MetadataShow full item record
AbstractTwo hundred forty-six adults with advanced progressive soft tissue sarcoma received combination chemotherapy with cyclophosphamide, vincristine, Adriamycin (doxorubicin), and DTIC. They were randomly allocated to receive the four drugs simultaneously every 4 weeks (S1: CYVADIC), or pairs of drugs (S2: ADIC-CYV) alternating at 4 weekly intervals. One hundred sixty-two patients completed 8 weeks of chemotherapy, and were considered to be evaluable for response. There were 18 complete remissions and 25 partial remissions, an overall response rate of 26%, with a highly significant difference between the two arms in favor of S1 (38% versus 14%, P = 0.001). There were no significant differences between S1 and S2 in terms of median duration of remissions (62 versus 39 weeks), and median survival of responders (85 versus 80 weeks) and of all evaluable patients (43 versus 45 weeks). Karnofsky index (KI) was the single most important prognostic factor. Patients with KI 90-100 showed a remission rate of 41% (56% on the S1 regimen) in contrast with 14% in those with KI 50-80. No patient with a KI of 50 responded to chemotherapy. The main toxicities were nausea, vomiting, anorexia, alopecia and myelosuppression, but did not differ significantly between the two regimens. Our findings suggest that stratification according to KI is essential for studies on chemotherapy for advanced soft tissue sarcomas in order to make a valuable comparison of treatment results.
CitationCyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. 1984, 53 (9):1825-32 Cancer
- Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.
- Authors: Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP
- Issue date: 1980 Jan
- Alternating combination chemotherapy of advanced soft tissue sarcomas in adults.
- Authors: Lopez M, Di Lauro L, Papaldo P, Perno CF
- Issue date: 1984 Oct
- Cyclophosphamide, adriamycin, DTIC and vincristine with methotrexate in the treatment of advanced soft tissue sarcomas.
- Authors: Pfeffer MR, Sulkes A, Biran S
- Issue date: 1988 Sep-Oct
- Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
- Authors: Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E
- Issue date: 1995 Jul
- [A combination chemotherapy with adriamycin, cyclophosphamide and DTIC (ACD) for advanced adult soft part sarcoma].
- Authors: Ikeda K, Ogawa M, Inagaki J, Horikoshi N, Inoue K, Usui N, Nakada H, Adachi K, Okada Y
- Issue date: 1984 Feb